Buy Anti-Mouse OMG Polyclonal Antibody

Catalog No.

PMD59001

Species reactivity

Mouse

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Mouse OMG (Leu28-Gly251).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Oligodendrocyte-myelin glycoprotein

Purification

Purified by antigen affinity column.

Accession

Q63912

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Western Blot

Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with OMG antibody (PMD59001) at 1 μg/ml.

Lane 1: Recombinant protein

Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

Predict MW: 28 kDa
Observed MW: 28 kDa

Clinical characteristics and treatment outcomes of ocular myasthenia gravis at a tertiary eye care center in Eastern India., PMID:40444309

Anti-Acetylcholine Receptor antibodies in Tear for the Diagnosis of Ocular Myasthenia Gravis., PMID:40383359

Multivariable Prediction Model for Suspected Ocular Myasthenia Gravis: Development and Validation., PMID:40257852

Immune Checkpoint Inhibitor-Induced Ocular Myasthenia Gravis: Case Series and Literature Review., PMID:40189747

Effects of omega-3 polyunsaturated fatty acid supplementation to first-calf beef heifers during late gestation on offspring physiology and performance., PMID:40126062

Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases., PMID:39872535

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study., PMID:39839222

[Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report]., PMID:39690779

Ocular Myasthenia gravis: determining the predictive factors of secondary generalisation., PMID:39621280

Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series., PMID:39592974

Analysis of clinical features and outcomes in patients with ocular myasthenia gravis according to anti-acetylcholine receptor antibody-seropositivity., PMID:39356387

Clinical characteristics and therapeutic effect of myasthenia gravis coexisting with thyroid eye disease., PMID:39196497

Ocular versus generalized myasthenia gravis: a continuum associated with acetylcholine receptor antibody titers., PMID:39190980

Efgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review., PMID:39148733

A genome-wide association study of alloimmunization in the TOPMed OMG-SCD cohort identifies a locus on chromosome 12., PMID:38966903

Prevalences of Other Non-Thyroid Autoimmune Diseases and Factor Associated with Their Presence in Ocular Myasthenia Gravis., PMID:38686013

Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia., PMID:38669629

Recommendations for the management of myasthenia gravis in Belgium., PMID:38649556

Clinical features of double seronegative ocular myasthenia gravis., PMID:38416235

Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study., PMID:38205656

Effectiveness of early glucocorticoids in myasthenia gravis: a retrospective cohort study., PMID:38187148

Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse., PMID:38159470

[A case of anti-acetylcholine receptor antibody-positive ocular myasthenia gravis with anti-titin antibody and anti-Kv1.4 antibody positive inflammatory myopathy]., PMID:37989286

Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort., PMID:37421800

Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis., PMID:36988830

Age of onset and factors affecting treatment responses in ocular myasthenia gravis., PMID:36879110

Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma., PMID:36875532

Ocular Myasthenia Gravis: A Current Overview., PMID:36778719

Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China., PMID:36712441

Ophthalmologic clinical features of ocular myasthenia gravis., PMID:36637960

Prognostic predictors of remission in ocular myasthenia gravis., PMID:36474006

Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis., PMID:36469201

Generalization of ocular myasthenia gravis 10 years after onset., PMID:36001142

Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis., PMID:35945595

Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis., PMID:35874731

Ocular Myasthenia: Clinical Course and the Diagnostic Utility of Assaying Acetylcholine Receptor Antibodies., PMID:35859633

[Acupuncture combined with western medication for ocular myasthenia gravis: a randomized controlled trial]., PMID:35793884

Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset., PMID:35547386

Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas., PMID:35474089

The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review., PMID:35280301

Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes., PMID:35246057

Differences in immunophenotypes between myasthenia gravis patients with and without thyroid antibodies., PMID:35147983

Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study., PMID:34729706

Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: A 5-year analysis., PMID:34717528

Serum irisin levels in patients with myasthenia gravis., PMID:34709479

COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series., PMID:34696220

Myelin-associated proteins are potential diagnostic markers in patients with primary brain tumour., PMID:34601991

Diagnostic yields and clinical features of ocular myasthenia gravis., PMID:34160444

Central Role of T Follicular Helper Cells in Myasthenia Gravis., PMID:33795956

Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort., PMID:33684630

Document Download

Anti-Mouse OMG Polyclonal Antibody.pdf

Anti-Mouse OMG Polyclonal Antibody